Revelation Biosciences, Inc.
REVB Nasdaq
SEC CIK 1810560
Follow Revelation Biosciences
Weekly email: filings, results
Net income
−$3.3M
−73.8% vs same quarter last year
EPS, diluted
−$5.92
Operating cash flow
−$2.4M
−48.6% vs same quarter last year
Operating income
−$3.4M
−74.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$8.9M |
| FY24 | −$15M |
| FY23 | −$120.3K |
| FY22 | −$10.8M |
| FY21 | −$12M |
| FY20 | −$1.6M |
| FY19 | −$3.6K |